Immunotherapy plus chemotherapy for malignant mesothelioma
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemotherapy helps people with malignant mesothelioma live longer and feel better. It's for patients who can't have surgery or radiation, and it may be an option if you haven't had treatment before or have had limited prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of malignant mesothelioma.
- Your tumor must not be removable by surgery or treatable with radiation.
- Depending on the phase of the study, you must have either had no prior treatment, one prior line of therapy, or up to three prior lines.
- You must be in generally good health (able to carry out daily activities with little or no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This Phase 1/2 study tests the immune medicines durvalumab and tremelimumab, with or without chemotherapy, given before surgery for mesothelioma. It aims to shrink the tumor and improve safety and outcomes so more patients can have their cancer fully removed.
This trial tests whether adding more chemotherapy directly into the belly after surgery can improve outcomes for people with a specific type of peritoneal mesothelioma. It may help reduce the chance of the cancer coming back.
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
This trial is testing a new immunotherapy drug (ivonescimab) combined with chemotherapy for people with mesothelioma that has already been treated. It aims to see if this combination can shrink tumors or slow the disease.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.